BC Innovations | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
BC Week In Review | Feb 15, 2019
Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
BC Extra | Feb 11, 2019
Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
BC Innovations | Jan 16, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Endoplasmic reticulum aminopeptidase 1 (ERAP1; ARTS1; ERAAP); ERAP2; insulin-regulated aminopeptidase (IRAP) In vitro and mouse studies identified inhibitors of ERAP1, ERAP2 and IRAP that...
Items per page:
1 - 5 of 5